Thierry Chardès

2.8k total citations
71 papers, 2.0k citations indexed

About

Thierry Chardès is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Thierry Chardès has authored 71 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Radiology, Nuclear Medicine and Imaging, 29 papers in Molecular Biology and 25 papers in Oncology. Recurrent topics in Thierry Chardès's work include Monoclonal and Polyclonal Antibodies Research (39 papers), HER2/EGFR in Cancer Research (16 papers) and Toxoplasma gondii Research Studies (11 papers). Thierry Chardès is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (39 papers), HER2/EGFR in Cancer Research (16 papers) and Toxoplasma gondii Research Studies (11 papers). Thierry Chardès collaborates with scholars based in France, United States and Morocco. Thierry Chardès's co-authors include Daniel Bout, André Pèlegrin, Isabelle Bourguin, Marie-Noëlle Mévélec, Cédric Bès, Dominique Buzoni–Gatel, Christel Larbouret, Sylvie Péraldi‐Roux, Martine Pugnière and Isabelle Navarro‐Teulon and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Immunology.

In The Last Decade

Thierry Chardès

70 papers receiving 2.0k citations

Peers

Countries citing papers authored by Thierry Chardès

Since Specialization

Citations

This map shows the geographic impact of Thierry Chardès's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Chardès with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Chardès more than expected).

Fields of papers citing papers by Thierry Chardès

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry Chardès. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Chardès. The network helps show where Thierry Chardès may publish in the future.

Co-authorship network of co-authors of Thierry Chardès

This figure shows the co-authorship network connecting the top 25 collaborators of Thierry Chardès. A scholar is included among the top collaborators of Thierry Chardès based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry Chardès. Thierry Chardès is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anti‐cathepsin D immunotherapy triggers both innate and adaptive anti‐tumour immunity in breast cancer 2023 ·British Journal of Pharmacology ·(unknown), Aude Mallavialle, Julien Faget, Lindsay B. Alcaraz, Marion Lapierre, (unknown), Valérie Laurent‐Matha, (unknown), Marta Jarlier, Pierre Martineau, Pascal Roger, Séverine Guiu, Thierry Chardès, Emmanuelle Liaudet‐Coopman	9
2	SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity 2022 ·International Journal of Cancer ·Lindsay B. Alcaraz, Aude Mallavialle, Caroline Mollévi, Florence Boissière‐Michot, (unknown), Joëlle Simony-Lafontaine, Valérie Laurent‐Matha, Thierry Chardès, William Jacot, Andrei Turtoï, Pascal Roger, Séverine Guiu, Emmanuelle Liaudet‐Coopman	19
3	Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking 2020 ·Cancer Science ·(unknown), Véronique Garambois, Nadège Gaborit, Christel Larbouret, Astrid Musnier, Pierre Martineau, André Pèlegrin, Thierry Chardès	3
4	Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells 2020 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), (unknown), (unknown), Julien Fraisse, Marta Jarlier, Florence Boissière‐Michot, Hélène Perrochia, (unknown), Véronique Garambois, Nathalie Bonnefoy, Henri‐Alexandre Michaud, Thierry Chardès, Diégo Tosi, André Pèlegrin, D. Azria, Christel Larbouret, C. Bourgier	8
5	A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions 2019 ·mAbs ·(unknown), (unknown), Christophe Arnoult, Thomas Bourquard, Marta Jarlier, Muriel Busson, (unknown), Martine Cérutti, Martine Pugnière, David Ternant, Nadège Gaborit, Thierry Chardès, Anne Poupon, Valérie Gouilleux‐Gruart, André Pèlegrin, Marie‐Alix Poul	20
6	ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells 2019 ·Cell Communication and Signaling ·Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, (unknown), Christel Larbouret, (unknown), Marie‐Alix Poul, Jean‐Marc Barret, Jean‐François Prost, André Pèlegrin, Thierry Chardès	13
7	Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3 2017 ·Molecular Cancer Therapeutics ·Christophe Le Clorennec, Hervé Bazin, Olivier Dubreuil, Christel Larbouret, Charline Ogier, Yassamine Lazrek, Véronique Garambois, Marie‐Alix Poul, Philippe Mondon, Jean‐Marc Barret, Gérard Mathis, Jean‐François Prost, André Pèlegrin, Thierry Chardès	13
8	Examination of HER3 targeting in cancer using monoclonal antibodies 2015 ·Proceedings of the National Academy of Sciences ·Nadège Gaborit, Ali Abdul‐Hai, Maicol Mancini, Moshit Lindzen, Sara Lavi, Orith Leitner, (unknown), (unknown), (unknown), (unknown), Christel Larbouret, Thierry Chardès, Hervé Bazin, André Pèlegrin, Michael Sela, Yosef Yarden	35
9	Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy 2013 ·Oncogene ·Wilhem Leconet, Christel Larbouret, Thierry Chardès, (unknown), (unknown), Muriel Busson, Marta Jarlier, (unknown), Martine Pugnière, Florence Bernex, Frédérique Penault‐Llorca, Jean‐Max Pasquet, André Pèlegrin, Bruno Robert	81
10	Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation 2013 ·Neoplasia ·Yassamine Lazrek, Olivier Dubreuil, Véronique Garambois, Nadège Gaborit, Christel Larbouret, Christophe Le Clorennec, (unknown), Wilhem Leconet, Marta Jarlier, Martine Pugnière, Nadia Vié, Bruno Robert, Céline Monnet, Khalil Bouayadi, (unknown), Philippe Mondon, André Pèlegrin, Thierry Chardès	35
11	Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice 2011 ·Breast Cancer Research ·Maha Zohra Ladjemi, Thierry Chardès, Stéphanie Corgnac, Véronique Garambois, (unknown), Bruno Robert, Caroline Mollévi, (unknown), (unknown), Jean‐Pierre Pouget, André Pèlegrin, Isabelle Navarro‐Teulon	16
12	Anti-HER2 vaccines: new prospects for breast cancer therapy 2010 ·Cancer Immunology Immunotherapy ·Maha Zohra Ladjemi, (unknown), Thierry Chardès, André Pèlegrin, Isabelle Navarro‐Teulon	110
13	In Vitro Antitumoral Activity of Baculovirus-expressed Chimeric Recombinant Anti-CD4 Antibody 13B8.2 on T-cell Lymphomas 2007 ·Journal of Immunotherapy ·(unknown), (unknown), Martine Cérutti, (unknown), Daniel Olive, Cédric Bès, Thierry Chardès	5
14	Application of the Spot method to the identification of peptides and amino acids from the antibody paratope that contribute to antigen binding 2002 ·Journal of Immunological Methods ·Daniel Laune, Franck Molina, (unknown), (unknown), Cédric Bès, (unknown), Thierry Chardès, Claude Granier	77
15	Thyroid Peroxidase Autoantibodies Obtained from Random Single Chain Fv Libraries Contain the Same Heavy/Light Chain Combinations as Occurin Vivo 2001 ·Endocrinology ·(unknown), Thierry Chardès, (unknown), Martine Pugnière, (unknown), (unknown), (unknown), Sylvie Péraldi‐Roux	20
16	Expression of a neuronal isoform of Nitric Oxide Synthase in rat pancreatic B cells 1999 ·Diabetologia ·(unknown), (unknown), Sylvie Péraldi‐Roux, Thierry Chardès, Pellegrino Masiello, Gérard Ribes, R. Gross	2
17	Anti‐digoxin scFv fragments expressed in bacteria and in insect cells have different antigen binding properties 1998 ·FEBS Letters ·(unknown), Thierry Chardès, Céline Montavon, Hassan Chaabihi, Jean‐Claude Mani, Martine Pugnière, Martine Duonor-Cérutti, G. Devauchelle, (unknown), (unknown)	21
18	Mucosal immune response in toxoplasmosis 1993 ·Research in Immunology ·Thierry Chardès, Daniel Bout	12
19	Immunological characterization of a 17-kDa antigen fromCryptosporidium parvumrecognized early by mucosal IgA antibodies 1992 ·FEMS Microbiology Letters ·Jean-Michel Répérant, Muriel Naciri, Thierry Chardès, Daniel Bout	36
20	Amplification of the secretory IgA response toToxoplasma gondiiusing cholera toxin 1991 ·FEMS Microbiology Letters ·Isabelle Bourguin, Thierry Chardès, Marie-Noëlle Mévélec, (unknown), Daniel Bout	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact